29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
25 citations
,
May 2003 in “Expert Opinion on Therapeutic Patents” Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
21 citations
,
January 2015 in “The Journal of Steroid Biochemistry and Molecular Biology” Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
20 citations
,
March 2017 in “Journal of cutaneous pathology” Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.
17 citations
,
January 2010 in “Acta Dermato Venereologica” EGFR inhibitors can cause yellowish skin eruptions.
16 citations
,
March 2018 in “Seminars in Oncology” The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
14 citations
,
January 2020 in “Mediterranean Journal of Rheumatology” New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
3 citations
,
September 2023 in “Frontiers in immunology” Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
3 citations
,
April 2019 in “Journal of Dermatological Treatment” Caffeine shows promise for treating some types of hair loss, but more research is needed.
3 citations
,
May 2018 in “Biochemical and Biophysical Research Communications” iNOS contributes to hair loss in obese diabetic mice and blocking it may encourage hair growth.
3 citations
,
August 2013 in “Stem cells” Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
3 citations
,
January 2011 in “Annals of Dermatology” Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
June 2026 in “Frontiers in Bioengineering and Biotechnology” Hair follicle systems are being engineered to better mimic natural hair follicles for studying hair disorders and testing treatments.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
March 2026 in “Frontiers in Medicine” Different types of alopecia cause hair loss due to immune system issues, with some allowing regrowth and others causing permanent loss.
March 2026 in “Brazilian Journal of Microbiology” Restoring skin bacteria may help reduce hair loss.